Tango Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tango Therapeutics Inc
Access all reports
Tango Therapeutics Inc. is a biotechnology firm focused on the discovery and development of innovative treatments for cancer. The company's research is centered on creating drugs that target specific genetic vulnerabilities in cancer cells. One of its leading projects, TNG908, is a synthetic lethal small molecule inhibitor designed for treating cancers characterized by methylthioadenosine phosphorylase deletions. Additionally, Tango Therapeutics is developing several other compounds, including TNG462 for similar indications, TNG260 targeting repressor element-1 silencing transcription, TNG348 aimed at BRCA1 or BRCA2-mutant cancers, and another compound targeting STK11-mutant cancers. The company is based in Boston, Massachusetts and its shares are listed on the Nasdaq.
Key slides for Tango Therapeutics Inc
Corporate Presentation
Tango Therapeutics Inc
Corporate Presentation
Tango Therapeutics Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
TNGX
Country
🇺🇸 United States